HOLX vs. ABT: Which Medical Technology Stock Is the Better Investment?
Hologic's $18.3B buyout deal and Abbott's strong growth across key segments set up a close contest for MedTech investors.
Gear Up for Hologic (HOLX) Q4 Earnings: Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Hologic (HOLX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2025.
HOLX or IDXX: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Instruments stocks have likely encountered both Hologic (HOLX) and Idexx Laboratories (IDXX). But which of these two stocks is more attractive to value investors?
Buy, Hold or Sell Hologic Stock? Key Insights Ahead of Q4 Earnings
HOLX's fiscal Q4 2025 earnings may face limits as macro pressures and slow Diagnostics curb momentum.
Hologic Stock Rises as Report Says Blackstone and TPG in Advanced Takeover Talks
The maker of women's health products rejected a $16 billion offer from the parties in May.
Why the Market Dipped But Hologic (HOLX) Gained Today
Hologic (HOLX) reached $68.5 at the closing of the latest trading day, reflecting a +2.24% change compared to its last close.
HOLX's Enhanced Fibroid Treatment Portfolio Powers GYN Surgical Growth
Hologic's GYN Surgical segment gains momentum internationally as expanded fibroid treatments support growth.
Hologic Expands Panther Fusion's Menu With Diagnostic Innovation
HOLX expands its Panther Fusion platform with new GI bacterial assays, securing FDA and EU approvals to boost Diagnostics growth.
HOLX Stock Gains on FDA & CE Approval for Automated Molecular GI Tests
Hologic's shares rise after receiving FDA clearance and CE mark for its rapid molecular GI assays on the Panther Fusion platform.
Hologic Bets on Endomagnetics to Fuel Interventional Breast Momentum
HOLX's Interventional Breast business hits $100M as Endomag products boost recurring revenues and margins.
Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.
HOLX to Discontinue Fluoroscan InSight FD Soon: Will the Stock Suffer?
Hologic set to end sales of Fluoroscan InSight FD in 2025 but sees strong momentum from DXA systems and broader business growth.
